- Home
- POR vs PCVX Comparison
POR vs PCVX Comparison
Compare POR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POR
- PCVX
- Stock Information
- Founded
- POR 1889
- PCVX 2013
- Country
- POR United States
- PCVX United States
- Employees
- POR N/A
- PCVX N/A
- Industry
- POR Electric Utilities: Central
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- POR Utilities
- PCVX Health Care
- Exchange
- POR Nasdaq
- PCVX Nasdaq
- Market Cap
- POR 4.7B
- PCVX 4.0B
- IPO Year
- POR N/A
- PCVX 2020
- Fundamental
- Price
- POR $43.82
- PCVX $41.05
- Analyst Decision
- POR Hold
- PCVX Strong Buy
- Analyst Count
- POR 11
- PCVX 8
- Target Price
- POR $46.30
- PCVX $114.17
- AVG Volume (30 Days)
- POR 1.1M
- PCVX 2.0M
- Earning Date
- POR 10-31-2025
- PCVX 11-04-2025
- Dividend Yield
- POR 4.81%
- PCVX N/A
- EPS Growth
- POR N/A
- PCVX N/A
- EPS
- POR 2.72
- PCVX N/A
- Revenue
- POR $3,488,000,000.00
- PCVX N/A
- Revenue This Year
- POR $4.88
- PCVX N/A
- Revenue Next Year
- POR $4.79
- PCVX N/A
- P/E Ratio
- POR $16.02
- PCVX N/A
- Revenue Growth
- POR 8.53
- PCVX N/A
- 52 Week Low
- POR $39.55
- PCVX $27.66
- 52 Week High
- POR $49.85
- PCVX $118.62
- Technical
- Relative Strength Index (RSI)
- POR 58.21
- PCVX 71.05
- Support Level
- POR $42.58
- PCVX $31.89
- Resistance Level
- POR $44.22
- PCVX $43.76
- Average True Range (ATR)
- POR 0.62
- PCVX 1.88
- MACD
- POR 0.04
- PCVX 1.02
- Stochastic Oscillator
- POR 84.56
- PCVX 79.32
About POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation along with 100 megawatts of energy storage.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.